Companies
Demetrix
engineers yeast peroxisomes to boost β-myrcene production — multicopy integration of the β-myrcene synthase fusion with peroxisome localization into Ty1 loci enhances the GPP precursor supply.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Secured over $60 million in venture-led funding, including an $11 million Series Seed and a $50 million Series A round | prnewswire.com |
| Capacity | Capable of producing metric tons of cannabinoids annually | berkeleyside.org · prnewswire.com |
| Headcount | About 100 people as of June 2022 | berkeleyside.org |
| Production site | Uses a third-party contract manufacturing organization (CMO) that is an FDA-registered, food cGMP-compliant facility; operates a 16,000 square foot R&D facility in Berkeley, California | berkeleyside.org · prnewswire.com |
| Revenue | Expected to bring multi-million dollars of revenue in 2022 medium confidence | prnewswire.com |
Independent sources: berkeleyside.org · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cell factories for flavors & fragrances | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.